Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 22 of 22 results for aflibercept

  1. Dexamethasone intravitreal implant for treating diabetic macular oedema (TA824)

    Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating visual impairment caused by diabetic macular oedema in adults.

  2. Aflibercept for untreated retinopathy in babies born preterm TS ID 11943

      Status ...

  3. Diabetic retinopathy: management and monitoring (NG242)

    This guideline covers managing and monitoring diabetic retinopathy in people under the care of hospital eye services. This includes non-proliferative and proliferative diabetic retinopathy, and diabetic macular oedema.

  4. Stopping rules for antiangiogenic treatment for late AMD (wet):- When should anti-vascular endothelial growth factor (VEGF) treatment be suspended or stoppedin people with late AMD (wet)?

    associated with inconvenience, risk of adverse events and – especially when aflibercept or ranibizumab is used – substantial costs....

  5. Ranibizumab for treating choroidal neovascularisation associated with pathological myopia (TA298)

    Evidence-based recommendations on ranibizumab (Lucentis) for treating choroidal neovascularisation associated with pathological myopia in adults.

  6. Past appeals and decisions

    raltitrexed 8 January 2002 TA307 Colorectal cancer (metastatic) – aflibercept 23 January 2014 TA118 Colorectal cancer (metastatic) -...

  7. Visual impairment due to myopic choroidal neovascularisation: aflibercept (ESNM76)

    This evidence summary has been replaced by NICE technology appraisal guidance 486.